Antibiotic Trial Network Could Emerge From FDA/NIH Workshop
This article was originally published in The Pink Sheet Daily
Executive Summary
Master trial protocols aimed at a patients with resistant organisms could streamline product development once sponsors are ready to “pay to play.”